Recombinant Microbial Lipase SLV339 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 298 | Hereditary pancreatitis | 1 |
298. Hereditary pancreatitis
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00630279 (ClinicalTrials.gov) | February 2008 | 22/2/2008 | Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis | A Multi-center, Single-blind, Parallel-design, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate Oral Recombinant Microbial Lipase Efficacy in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis | Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis | Drug: Placebo;Drug: Recombinant Microbial Lipase SLV339 | Solvay Pharmaceuticals | NULL | Terminated | 18 Years | N/A | Both | 56 | Phase 2 | Czech Republic;Denmark;Hungary;Latvia;Poland;Russian Federation;Sweden |